March 18, 2016: Here are four stocks trading with heavy volume among 25 equities making new 52-week lows in Friday’s session.
Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped another 10% on Friday to post a new 52-week low at $26.72 after closing at $29.69 on Thursday. The stock’s 52-week high is $263.81. Share volume of about 53 million was more than 4 times the daily average of around 12.6 million shares traded. No more bad news on Friday, just more of the same selling we’ve seen all week.
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) fell by about 20% on Friday to post a new 52-week low of $2.71 against a high of $10.15. The stock closed at $3.40 on Thursday night. Volume rose to around 8 million shares, about 4 times the daily average of around 2.2 million shares traded. The company said this morning that some senior debt holders had converted debt to shares at an implied price of $2.47 per share.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) posted a new 52-week low on Friday. Shares traded at a low of $52.62, down about 1.6%, after closing at $53.50 on Thursday. The stock’s 52-week high is $72.31. Volume totaled about 10% above the daily average of around 5.3 million shares. No news, just caught in the Valeant wake.
Akorn Inc. (NASDAQ: AKRN) dropped about 8% on Friday to post a new 52-week low of $17.57 against a 52-week high of $57.10. The stock closed at $19.09 on Thursday night. Volume rose to more than double the stock’s daily average volume of around 1.8 million. The pharmaceuticals maker had no specific news on Friday.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
